

# CITATION REPORT

List of articles citing

**Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype**

**DOI: 10.1158/1078-0432.ccr-04-2424**  
**Clinical Cancer Research, 2005, 11, 5175-80.**

**Source:** <https://exaly.com/paper-pdf/38813431/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
547	Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. <b>2005</b> , 70, 93-7		18
546	[Prophylactic surgery of mammary and ovarian carcinoma]. <b>2005</b> , 76, 1145-54		3
545	Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <b>2006</b> , 8, R72		54
544	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1533-9	12.9	282
543	Molecular classification of breast tumors: toward improved diagnostics and treatments. <b>2007</b> , 360, 91-114		50
542	The Basal Phenotype of BRCA1-Related Breast Cancer. <b>2006</b> , 17, 22-25		
541	Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. <b>2006</b> , 66, 4636-44		235
540	Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. <b>2006</b> , 42, 650-5		11
539	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. <b>2006</b> , 42, 3149-56		164
538	Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report. <b>2006</b> , 4, 28-38		10
537	Basic science (July 2005). <b>2006</b> , 9, 1-3		
536	Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. <b>2006</b> , 30, 1357-66		36
535	Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer. <b>2006</b> , 7, 29		1
534	Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. <b>2006</b> , 49, 22-34		257
533	Metaplastic breast carcinomas are basal-like tumours. <b>2006</b> , 49, 10-21		244
532	Histopathological features of breast cancer in carriers of ATM gene variants. <b>2006</b> , 49, 523-32		16
531	Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. <b>2006</b> , 19, 1506-11		103

530	Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. <b>2006</b> , 25, 5837-45	87
529	Basal-like breast cancer and the BRCA1 phenotype. <b>2006</b> , 25, 5846-53	368
528	Clinical management of BRCA1 and BRCA2 mutation carriers. <b>2006</b> , 25, 5825-31	69
527	Histopathology of BRCA1- and BRCA2-associated breast cancer. <b>2006</b> , 59, 27-39	73
526	Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. <b>2006</b> , 99, 85-90	111
525	The basal phenotype of BRCA1-related breast cancer: past, present and future. <b>2006</b> , 5, 963-7	43
524	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. <b>2007</b> , 60, 1006-12	78
523	Basal-like breast carcinomas: clinical outcome and response to chemotherapy. <b>2006</b> , 59, 729-35	213
522	Reply to the Letter to the Editor by van Diest, et al. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 671-671	12.9
521	Demystifying basal-like breast carcinomas. <b>2007</b> , 60, 1328-32	41
520	EGFR expression predicts BRCA1 status in patients with breast cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 670; author reply 671	12.9 9
519	Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). <b>2006</b> , 98, 535-44	161
518	MYC amplification in breast cancer: a chromogenic in situ hybridisation study. <b>2007</b> , 60, 1017-23	50
517	In Reply. <b>2006</b> , 24, 3313-3314	4
516	Risk prediction models for familial breast cancer. <b>2006</b> , 2, 257-74	72
515	A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase. <b>2007</b> , 104, 6614-9	40
514	Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case-control study. <b>2007</b> , 96, 850-5	7
513	Cancer du sein. <b>2007</b> ,	2

512	Gene-expression analysis and the basal-like breast cancer subtype. <b>2007</b> , 3, 55-63	29
511	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. <b>2007</b> , 104, 12111-6	343
510	Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. <b>2007</b> , 16, 740-6	56
509	Hereditary Breast Cancer. <b>2007</b> ,	
508	Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. <b>2007</b> , 99, 1683-94	163
507	The phenotypic spectrum of basal-like breast cancers: a critical appraisal. <b>2007</b> , 14, 358-73	64
506	BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. <b>2007</b> , 31, 121-8	128
505	Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. <b>2007</b> , 14, 419-30	97
504	Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. <b>2007</b> , 31, 501-8	53
503	Basal-Like Breast Cancers. <b>2007</b> , 12, 143-153	7
502	Chromogenic and fluorescent in situ hybridization in breast cancer. <b>2007</b> , 38, 1105-22	77
501	Triple-negative breast cancer: therapeutic options. <b>2007</b> , 8, 235-44	664
500	Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?. <b>2007</b> , 9, R82	51
499	P-cadherin expression in breast cancer: a review. <b>2007</b> , 9, 214	72
498	Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. <b>2007</b> , 9, R65	454
497	An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). <b>2007</b> , 9, 104	121
496	Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. <b>2007</b> , 9, R4	230
495	Triple-negative breast cancer: clinical features and patterns of recurrence. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 4429-34	12.9 2961

494	BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer. <b>2007</b> , 30, 316-8	10
493	Tissue microarrays for testing basal biomarkers in familial breast cancer cases. <b>2007</b> , 125, 226-30	3
492	Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. <b>2007</b> , 28, 477-85	40
491	Moesin expression is a marker of basal breast carcinomas. <b>2007</b> , 121, 1779-85	63
490	The aged breast. <b>2007</b> , 211, 232-40	25
489	A mouse model of basal-like breast carcinoma with metaplastic elements. <b>2007</b> , 211, 389-98	118
488	BRCA1 dysfunction in sporadic basal-like breast cancer. <b>2007</b> , 26, 2126-32	466
487	Triple negative tumours: a critical review. <b>2008</b> , 52, 108-18	640
486	Expression profiling technology: its contribution to our understanding of breast cancer. <b>2008</b> , 52, 67-81	34
485	The disappearing Barr body in breast and ovarian cancers. <b>2007</b> , 7, 628-33	89
484	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. <b>2007</b> , 20, 474-81	179
483	Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. <b>2007</b> , 20, 1298-306	44
482	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. <b>2007</b> , 50, 434-8	132
481	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. <b>2007</b> , 7, 134	284
480	Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. <b>2007</b> , 7, 160	41
479	The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. <b>2007</b> , 16, 104-7	111
478	The prevention of hereditary breast cancer. <b>2007</b> , 34, 401-5	10
477	Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. <b>2007</b> , 72, 87-97	10

476	Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. <b>2007</b> , 101, 233-45	41
475	Scanning the horizon: what is the future of genome-wide association studies in accelerating discoveries in cancer etiology and prevention?. <b>2007</b> , 18, 479-84	18
474	Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. <b>2008</b> , 111, 303-11	28
473	High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. <b>2008</b> , 111, 475-80	64
472	The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. <b>2008</b> , 27, 523-37	83
471	The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. <b>2008</b> , 27, 691-705	137
470	Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. <b>2008</b> , 7, 83-9	27
469	Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. <b>2008</b> , 7, 233-44	16
468	Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. <b>2008</b> , 15, 153-8	29
467	"New" molecular taxonomy in breast cancer. <b>2008</b> , 10, 777-85	13
466	Hereditary breast cancer: new genetic developments, new therapeutic avenues. <b>2008</b> , 124, 31-42	233
465	The ubiquitin E3 ligase activity of BRCA1 and its biological functions. <b>2008</b> , 3, 1	78
464	The UPS: a promising target for breast cancer treatment. <b>2008</b> , 9 Suppl 1, S2	16
463	The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. <b>2008</b> , 112, 737-47	112
462	Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. <b>2008</b> , 29, 1292-303	51
461	Triple negative breast cancer: a new area for phase III breast cancer clinical trials. <b>2008</b> , 20, 35-9	33
460	The influence of basal phenotype on the metastatic pattern of breast cancer. <b>2008</b> , 20, 40-5	53
459	Molecular diagnosis in breast cancer. <b>2008</b> , 14, 202-213	8

458	Hereditary breast cancer: from molecular pathology to tailored therapies. <b>2008</b> , 61, 1073-82	35
457	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <b>2008</b> , 82, 937-48	218
456	Cyclin D1 expression analysis in familial breast cancers may discriminate BRCA1 from BRCA2-linked cases. <b>2008</b> , 21, 1262-70	15
455	The clinicopathologic characteristics and prognostic significance of triple-negative in node-negative breast cancer. <b>2008</b> , 8, 307	92
454	Genetic predisposition to breast cancer: past, present, and future. <b>2008</b> , 9, 321-45	202
453	Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. <b>2008</b> , 7, 29	28
452	The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. <b>2008</b> , 10, R108	42
451	Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. <b>2008</b> , 10, 401	20
450	Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. <b>2008</b> , 10, R17	23
449	The molecular pathology of hereditary breast cancer. <b>2008</b> , 75, 85-94	64
448	Expression of BRCA1 protein in breast cancer and its prognostic significance. <b>2008</b> , 39, 857-65	115
447	What is triple-negative breast cancer?. <b>2008</b> , 44, 2799-805	230
446	Can genetic testing guide treatment in breast cancer?. <b>2008</b> , 44, 2774-80	20
445	Basal carcinoma of the breast revisited: an old entity with new interpretations. <b>2008</b> , 61, 553-60	89
444	Basal-like breast cancer: a critical review. <b>2008</b> , 26, 2568-81	657
443	Development of therapeutic approaches to triple negative phenotype breast cancer. <b>2008</b> , 12, 1123-37	16
442	Breast carcinoma with basal phenotype: mammographic findings. <b>2008</b> , 191, 346-51	36
441	CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma. <b>2008</b> , 130, 724-30	35

440	Genetic susceptibility loci for breast cancer by estrogen receptor status. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 8000-9	12.9	105
439	Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. <b>2008</b> , 10, 383-95		24
438	Breast Cancer. <b>2008</b> ,		3
437	Stemming the tide of cancer for BRCA1/2 mutation carriers. <b>2008</b> , 26, 4239-43		2
436	Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6625-33	12.9	12
435	Is Basal-like Carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. <b>2008</b> , 75, 119-31		32
434	Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1976-83	12.9	21
433	Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis—a report from the kConFab Investigators. <b>2008</b> , 26, 1657-63		65
432	Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers. <b>2008</b> , 45, 765-6		1
431	Impact of basal-like breast carcinoma determination for a more specific therapy. <b>2008</b> , 75, 95-103		25
430	Clinical and pathologic aspects of basal-like breast cancers. <b>2008</b> , 5, 149-59		71
429	Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. <b>2008</b> , 45, 425-31		129
428	Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. <b>2008</b> , 3, 157-63		53
427	Genome-wide association studies in cancer. <b>2008</b> , 17, R109-15		196
426	Evaluation of morphologic features to identify "basal-like phenotype" on core needle biopsies of breast. <b>2008</b> , 16, 411-6		13
425	Histopathological features of BRCA1 familial breast cancers in the kConFab resource. <b>2008</b> , 40, 352-8		8
424	Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. <b>2009</b> , 23, 2563-77		431
423	The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1514-8	12.9	54



422	Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. <b>2009</b> , 62, 139-46	28
421	Update on genetic predisposition to breast cancer. <b>2009</b> , 9, 1103-13	10
420	Absence of germline BRCA1 mutations in familial pancreatic cancer patients. <b>2009</b> , 8, 131-5	40
419	Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?. <b>2009</b> , 18, 1467-77	12
418	Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. <b>2009</b> , 252, 358-68	58
417	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <b>2009</b> , 18, 4442-56	91
416	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. <b>2009</b> , 46, 811-7	65
415	Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. <b>2009</b> , 20, 609-14	30
414	Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?. <b>2009</b> , 18, 125-32	104
413	High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. <b>2009</b> , 69, 663-71	119
412	Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. <b>2009</b> , 62, 926-30	21
411	Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. <b>2009</b> , 7, 1304-9	95
410	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. <b>2009</b> , 69, 3589-96	114
409	Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. <b>2009</b> , 69, 565-72	304
408	Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. <b>2009</b> , 9, 360	3
407	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. <b>2009</b> , 9, 86	213
406	Genetic characterization of breast cancer and implications for clinical management. <b>2009</b> , 13, 4090-103	31
405	Therapeutic options for triple-negative breast cancers with defective homologous recombination. <b>2009</b> , 1796, 266-80	22

404	Histopathological criteria and selection algorithms for BRCA1 genetic testing. <b>2009</b> , 189, 105-11	13
403	Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. <b>2009</b> , 115, 4917-23	44
402	Cytological criteria to predict basal phenotype of breast carcinomas. <b>2009</b> , 37, 809-14	7
401	Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. <b>2009</b> , 100, 89-94	40
400	Treatment of metastatic breast cancer: looking towards the future. <b>2009</b> , 114, 413-22	30
399	Pattern of metastatic spread in triple-negative breast cancer. <b>2009</b> , 115, 423-8	369
398	Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. <b>2009</b> , 117, 183-91	43
397	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. <b>2009</b> , 116, 479-89	112
396	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. <b>2009</b> , 117, 371-9	10
395	Patho-biological aspects of basal-like breast cancer. <b>2009</b> , 113, 411-22	61
394	Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. <b>2009</b> , 118, 539-46	26
393	Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. <b>2009</b> , 8, 479-82	14
392	Basal phenotype in breast carcinoma occurring in women aged 35 or younger. <b>2009</b> , 15, 41-5	4
391	Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. <b>2009</b> , 16, 275-80	26
390	Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction. <b>2009</b> , 16, 268-74	9
389	Clinicopathological characteristics of triple-negative breast cancers. <b>2009</b> , 16, 254-9	27
388	Genome-wide association studies identify new breast cancer susceptibility genes. <b>2009</b> , 1, 131-138	3
387	Das hereditäre Mammakarzinom. <b>2009</b> , 42, 665-670	

386	Do Basal-like breast cancers really exist?. <b>2009</b> , 9, 128-34	89
385	Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. <b>2009</b> , 28, 843-53	155
384	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <b>2009</b> , 101, 1456-60	17
383	BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. <b>2009</b> , 101, 1168-74	51
382	The role of molecular analysis in breast cancer. <b>2009</b> , 41, 77-88	41
381	DNA methylation, epimutations and cancer predisposition. <b>2009</b> , 41, 34-9	56
380	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. <b>2009</b> , 9 Suppl 2, S73-81	424
379	Triple-negative/basal-like breast cancer: review. <b>2009</b> , 41, 40-7	204
378	Breast Cancer in the Post-Genomic Era. <b>2009</b> ,	3
377	Triple-negative breast cancer--current status and future directions. <b>2009</b> , 20, 1913-27	416
376	Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. <b>2009</b> , 45 Suppl 1, 11-26	50
375	Triple negative breast cancers: clinical and prognostic implications. <b>2009</b> , 45 Suppl 1, 27-40	173
374	[Basal-like breast cancer: a review]. <i>Annales De Pathologie</i> , <b>2009</b> , 29, 180-6	0.3 5
373	Triple-Negative Breast Carcinoma. <b>2009</b> , 2, 247-61	3
372	Genetic alterations and oncogenic pathways associated with breast cancer subtypes. <b>2009</b> , 7, 511-22	171
371	Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2302-10	12.9 371
370	Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. <b>2009</b> , 33, 1093-7	59
369	Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. <b>2009</b> , 41, 89-99	14

368	What is the difference between triple-negative and basal breast cancers?. <b>2010</b> , 16, 12-6	30
367	Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. <b>2010</b> , 16, 23-32	106
366	Genetic/familial high-risk assessment: breast and ovarian. <b>2010</b> , 8, 562-94	169
365	DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. <b>2010</b> , 86, 420-33	73
364	Das familiäre Mammakarzinom. <b>2010</b> , 43, 79-86	
363	BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel. <b>2010</b> , 9, 700-707	2
362	An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. <b>2010</b> , 121, 575-89	132
361	BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. <b>2010</b> , 122, 721-31	61
360	Subtypes of familial breast tumours revealed by expression and copy number profiling. <b>2010</b> , 123, 661-77	81
359	Combinatorial biomarker expression in breast cancer. <b>2010</b> , 120, 293-308	150
358	Health disparities in breast cancer: biology meets socioeconomic status. <b>2010</b> , 121, 281-92	76
357	Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. <b>2010</b> , 21, 839-46	11
356	The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. <b>2010</b> , 9, 545-53	18
355	Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. <b>2010</b> , 37, 384-401	31
354	Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. <b>2010</b> , 10, 568	32
353	BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. <b>2010</b> , 10, 654	46
352	Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study. <b>2010</b> , 19, 137-41	16
351	Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. <b>2010</b> , 49, 78-90	23

350	Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families. <b>2010</b> , 49, 1082-94	6
349	Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. <b>2010</b> , 31, E1484-505	48
348	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. <b>2010</b> , 102, 1091-8	40
347	Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. <b>2010</b> , 42, 410-4	540
346	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <b>2010</b> , 42, 885-92	276
345	Molecular characterization of breast cancer in young Brazilian women. <b>2010</b> , 56, 278-87	10
344	Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. <b>2010</b> , 12, 245-59	221
343	BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. <b>2010</b> , 28, 5265-73	142
342	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. <b>2010</b> , 70, 9742-54	147
341	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. <b>2010</b> , 19, 2886-97	56
340	Will molecular classification replace traditional breast pathology?. <b>2010</b> , 18, 1625-1665	15
339	Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. <b>2010</b> , 1, 812-21	167
338	The influence of common polymorphisms on breast cancer. <b>2010</b> , 155, 15-32	9
337	A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. <b>2010</b> , 47, 771-4	85
336	Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. <b>2010</b> , 10, 199-207	60
335	Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results. <b>2010</b> , 31, 76-8	4
334	Beyond triple-negative breast cancer: the need to define new subtypes. <b>2010</b> , 10, 1197-213	17
333	The Clinical Significance of Unknown Sequence Variants in BRCA Genes. <b>2010</b> , 2, 1644-60	26

332	Pathology of hereditary breast cancer. <b>2010</b> , 23 Suppl 2, S46-51	57
331	Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases. <b>2010</b> , 9, 266-73	10
330	Breast cancer predisposition syndromes. <b>2010</b> , 24, 799-814	16
329	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. <b>2010</b> , 28, 1145-53	734
328	Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy. <b>2010</b> , 41, 364-372	23
327	BRCA mutations in the management of breast cancer: the state of the art. <b>2010</b> , 7, 702-7	125
326	Triple-negative breast cancer. <b>2010</b> , 363, 1938-48	2458
325	DNA amplifications in breast cancer: genotypic-phenotypic correlations. <b>2010</b> , 6, 967-84	18
324	The role of BRCA mutation testing in determining breast cancer therapy. <b>2010</b> , 7, 708-17	74
323	Triple-negative breast cancer. <b>2010</b> , 12 Suppl 2, S3	165
322	Histological types of breast cancer: how special are they?. <b>2010</b> , 4, 192-208	255
321	Treatment options for patients with triple-negative breast cancer. <b>2010</b> , 3, 42	45
320	Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. <b>2010</b> , 12, R95	31
319	Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. <b>2010</b> , 23 Suppl 2, S60-4	241
318	Classification moléculaire des cancers du sein: utilité en clinique. <b>2010</b> , 34, 32-43	1
317	Common genetic variants and cancer risk in Mendelian cancer syndromes. <b>2010</b> , 20, 299-307	23
316	Targeting DNA repair in breast cancer: a clinical and translational update. <b>2010</b> , 36, 557-65	35
315	BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. <b>2010</b> , 7, 403-17	518

314	ORIGINAL ARTICLE: Immunohistochemical identification of basal-like breast carcinoma and its histopathologic correlation. <b>2010</b> , 3, 86-92	
313	Hereditary cancer: the challenges are pedigree interpretation, risk assessment, and management—not genetic testing. <b>2010</b> , 7, 82-83	
312	Biomarkers for Basal-like Breast Cancer. <b>2010</b> , 2, 1040-65	37
311	Triple-negative breast cancer: disease entity or title of convenience?. <b>2010</b> , 7, 683-92	588
310	Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. <b>2010</b> , 12, R57	23
309	Incorporating tumour pathology information into breast cancer risk prediction algorithms. <b>2010</b> , 12, R28	54
308	Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. <b>2010</b> , 12, R12	66
307	Principles of Clinical Cancer Genetics. <b>2010</b> ,	2
306	The Met oncogene and basal-like breast cancer: another culprit to watch out for?. <b>2010</b> , 12, 208	56
305	Triple-negative breast cancer: unique biology and its management. <b>2010</b> , 28, 878-83	11
304	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <b>2011</b> , 24, 157-67	447
303	Breast. <b>2011</b> , 225-247	1
302	Recent developments in treatment stratification for metastatic breast cancer. <b>2011</b> , 71, 2099-113	10
301	Handbook of Practical Immunohistochemistry. <b>2011</b> ,	5
300	Inherited Cancer Syndromes. <b>2011</b> ,	1
299	Therapeutic approaches for women predisposed to breast cancer. <b>2011</b> , 62, 295-306	28
298	Triple negative breast cancer: adjuvant chemotherapy effect on survival. <b>2011</b> , 56, 285-90	6
297	Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. <b>2011</b> , 179, 1061-72	14

296	Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. <b>2011</b> , 42, 153-65	5
295	Human epidermal growth factor receptor 2, Na <sup>+</sup> /H <sup>+</sup> exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. <b>2011</b> , 42, 1589-95	14
294	A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma. <b>2011</b> , 207, 583-6	3
293	Rare variants in the ATM gene and risk of breast cancer. <b>2011</b> , 13, R73	151
292	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <b>2011</b> , 13, R110	62
291	Challenges to developing proteomic-based breast cancer diagnostics. <b>2011</b> , 15, 251-9	18
290	CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. <b>2011</b> , 6, 638-49	82
289	BRCA1-related gene signature in breast cancer: the role of ER status and molecular type. <b>2011</b> , 3, 125-36	18
288	Predicting protein phenotypes based on protein-protein interaction network. <b>2011</b> , 6, e17668	26
287	Triple-Negative Breast Cancer: Clinical and Histological Correlations. <b>2011</b> , 6, 273-278	31
286	Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention. <b>2011</b> , 12, 1974-82	0
285	Genetics: predisposition and management. <b>2011</b> , 54, 180-90	0
284	Pathological Features of BRCA1/BRCA2 Mutation-Associated Breast Cancer: Implications for Diagnostics and Treatment. <b>2011</b> , 11, 114-121	
283	Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. <b>2011</b> , 108, 323-30	82
282	Breast cancer after bilateral risk-reducing mastectomy. <b>2011</b> , 79, 431-7	38
281	Phenotype-genotype correlation in familial breast cancer. <b>2011</b> , 16, 27-40	28
280	Inherited mutations in breast cancer genes--risk and response. <b>2011</b> , 16, 3-15	52
279	Nuclear and cytoplasmic expressions of ER $\alpha$ and ER $\beta$ are predictive of response to therapy and alters prognosis in familial breast cancers. <b>2011</b> , 126, 395-405	44



278	Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. <b>2011</b> , 128, 301-13	46
277	EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. <b>2011</b> , 127, 831-9	6
276	Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes. <b>2011</b> , 129, 593-606	44
275	Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. <b>2011</b> , 130, 145-53	79
274	Immunophenotypic predictive profiling of BRCA1-associated breast cancer. <b>2011</b> , 458, 55-64	25
273	Characteristics of triple-negative breast cancer. <b>2011</b> , 137, 183-92	172
272	Pathology of hereditary breast cancer. <b>2011</b> , 34, 71-88	98
271	New insights into the prevention and treatment of familial breast cancer. <b>2011</b> , 103, 294-8	3
270	Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. <b>2011</b> , 50, 71-81	47
269	CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry. <b>2011</b> , 117, 1350-9	12
268	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. <b>2011</b> , 24, 64-81	50
267	Exploring molecular pathways of triple-negative breast cancer. <b>2011</b> , 2, 870-9	57
266	Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. <b>2011</b> , 9, 3-13	83
265	Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. <b>2011</b> , 71, 2360-70	80
264	Handbook of Metastatic Breast Cancer. <b>2011</b> ,	
263	Triple-negative breast cancer: adjuvant therapeutic options. <b>2011</b> , 2011, 696208	43
262	Management options in triple-negative breast cancer. <b>2011</b> , 5, 175-99	29
261	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. <b>2011</b> , 22, 1561-1570	131

260	Basal phenotype breast cancer: implications for treatment and prognosis. <b>2011</b> , 7, 181-202	19
259	Old and new concepts in histopathological characterization of familial breast cancer. <b>2011</b> , 22 Suppl 1, i24-30	11
258	Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. <b>2012</b> , 7, e47993	37
257	Integrating breast cancer genetics into clinical practice. <b>2012</b> , 8, 99-112	4
256	Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer. <b>2012</b> , 72, 833-839	4
255	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. <b>2012</b> , 2, 366-375	295
254	Cancer du sein. <b>2012</b> ,	
253	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <b>2012</b> , 21, 134-47	411
252	Metabolic syndrome and triple-negative breast cancer: a new paradigm. <b>2012</b> , 2012, 809291	63
251	Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. <b>2012</b> , 2012, 829315	10
250	[Immunohistochemical characteristics of triple negative/basal-like breast cancer]. <b>2012</b> , 28, 238-44	2
249	Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. <b>2012</b> , 103, 129-45	27
248	Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers. <b>2012</b> , 36, 1483-8	9
247	Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35. <b>2012</b> , 18, 399-405	11
246	Molecular pathology of breast cancer: what a pathologist needs to know. <b>2012</b> , 138, 770-80	66
245	Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. <b>2012</b> , 160, 178-97	26
244	Cancers du sein triples ngatifs: Une revue de la littfature. <b>2012</b> , 571-588	
243	Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCA1, but not BRCA1 familial breast cancers. <b>2012</b> , 14, R69	32

242	Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. <b>2012</b> , 14, R142	36
241	Keratin expression in breast cancers. <b>2012</b> , 461, 313-22	58
240	Systemic therapy options in BRCA mutation-associated breast cancer. <b>2012</b> , 135, 355-66	45
239	The right time, the right place: will targeting human cancer-associated mutations to the mouse provide the perfect preclinical model?. <b>2012</b> , 22, 28-35	5
238	Dissecting the heterogeneity of triple-negative breast cancer. <b>2012</b> , 30, 1879-87	304
237	Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. <b>2012</b> , 12, 510	37
236	Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. <b>2012</b> , 43, 1932-9	5
235	Management of women with BRCA1/2 mutation-associated breast cancer. <b>2012</b> , 1, 157-164	
234	Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. <b>2011</b> , 50, 423-34	26
233	Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. <b>2012</b> , 15, 197-202	18
232	Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review. <b>2012</b> , 5, 345-66	19
231	Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy. <b>2012</b> , 118, 3893-8	20
230	BRACKing news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. <b>2012</b> , 31, 131-42	9
229	Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. <b>2012</b> , 134, 353-62	73
228	Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. <b>2012</b> , 133, 437-45	22
227	Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. <b>2012</b> , 133, 347-55	20
226	Epithelial E- and P-cadherins: role and clinical significance in cancer. <b>2012</b> , 1826, 297-311	107
225	Familial breast cancer. <b>2012</b> , 82, 105-14	122

224	Molecularly targeted therapies for metastatic triple-negative breast cancer. <b>2013</b> , 138, 21-35	109
223	First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. <b>2013</b> , 13, 46	28
222	The complex genetic landscape of familial breast cancer. <b>2013</b> , 132, 845-63	94
221	Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. <b>2013</b> , 140, 195-205	35
220	Klinik und Genetik des familiären Brust- und Eierstockkrebses. <b>2013</b> , 25, 259-277	2
219	Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. <b>2013</b> , 19, 189-92	27
218	Lack of expression of the proteins GMPR2 and PPAR $\alpha$ are associated with the basal phenotype and patient outcome in breast cancer. <b>2013</b> , 137, 127-37	15
217	Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. <b>2013</b> , 22, 986-92	31
216	Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. <b>2013</b> , 40, 475-512	9
215	BRCA1 is a negative modulator of the PRC2 complex. <b>2013</b> , 32, 1584-97	88
214	Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation. <b>2013</b> , 32, 2715-25	31
213	Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. <b>2013</b> , 8, 464-76	66
212	Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. <b>2013</b> , 50, 360-7	76
211	Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. <b>2013</b> , 10, 164-192	18
210	Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. <b>2013</b> , 73, 556-583	41
209	[Genetic diagnostics of cancer diseases]. <b>2013</b> , 102, 1475-82	2
208	EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. <b>2013</b> , 73, 6254-63	31
207	Personalized medicine for metastatic breast cancer. <b>2013</b> , 25, 615-24	4

206	Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. <b>2013</b> , 22, 2110-5	7
205	Molecular Classification and Prognostic Signatures of Breast Tumors. <b>2013</b> , 55-62	
204	Prediction of gene phenotypes based on GO and KEGG pathway enrichment scores. <b>2013</b> , 2013, 870795	26
203	Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. <b>2013</b> , 18, 909-16	46
202	Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. <b>2013</b> , 8, e64268	71
201	A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis. <b>2014</b> , 9, e101488	24
200	Invasive Breast Carcinoma. <b>2014</b> , 934-951	3
199	Prophylaktische Operationen. <b>2014</b> , 47, 741-745	1
198	Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy. <b>2014</b> , 39, 1588-94	11
197	Role of SPARC in bone remodeling and cancer-related bone metastasis. <b>2014</b> , 115, 17-26	39
196	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <b>2014</b> , 16, 3419	82
195	Taxonomy of breast cancer based on normal cell phenotype predicts outcome. <b>2014</b> , 124, 859-70	134
194	Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers. <b>2014</b> , 9, 385-9	10
193	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <b>2014</b> , 16, 3416	46
192	Identification of sequence polymorphisms in the mitochondrial displacement loop as risk factors for sporadic and familial breast cancer. <b>2014</b> , 35, 4773-7	14
191	[Risk-adapted surveillance: focus on familial breast and ovarian cancer]. <b>2014</b> , 57, 307-11	5
190	Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). <b>2014</b> , 16, 280-4	20
189	Genetic and Environmental Effects on Stem Cells and Breast Cancer. <b>2014</b> , 2, 27-32	

188	[Invasive breast cancer: the current WHO classification]. <b>2014</b> , 35, 7-17	23
187	Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. <b>2014</b> , 35, 967-73	88
186	Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. <b>2014</b> , 135, 2352-61	24
185	Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. <b>2014</b> , 6, 88-100	29
184	BRCA1 pathway function in basal-like breast cancer cells. <b>2014</b> , 34, 3828-42	32
183	Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. <b>2014</b> , 14, 570	73
182	Large deletion causing von Hippel-Lindau disease and hereditary breast cancer syndrome. <b>2014</b> , 12, 16	5
181	Effect of niclosamide on basal-like breast cancers. <b>2014</b> , 13, 800-11	62
180	Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. <b>2014</b> , 19, 173-81	8
179	Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. <b>2014</b> , 33, 679-89	285
178	[Breast cancer classification is evolving]. <b>2014</b> , 208, 251-9	
177	Hereditary breast cancer: clinical, pathological and molecular characteristics. <b>2014</b> , 8, 145-55	50
176	Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ER-negative breast tumorigenesis. <b>2015</b> , 15, 1026	23
175	BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14. <b>2015</b> , 21, 596-603	5
174	Hereditary Breast Cancer Syndromes: Molecular Pathogenesis and Diagnostics. <b>2015</b> , 1-16	1
173	The molecular and genetic basis of inherited cancer risk in gynaecology. <b>2015</b> , 17, 233-241	5
172	Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes. <b>2015</b> , 22, 306-13	11
171	Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. <b>2015</b> , 7, 39-49	9

170	Genetic and epigenetic signatures of breast cancer subtypes. <b>2012</b> , 4, 934-49	13
169	Biomarkers in triple negative breast cancer: A review. <b>2015</b> , 6, 252-63	65
168	Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. <b>2015</b> , 26, 95-100	54
167	The fate of chemoresistance in triple negative breast cancer (TNBC). <b>2015</b> , 3, 257-75	216
166	Overview of Genetically Engineered Mouse Models of Breast Cancer Used in Translational Biology and Drug Development. <b>2015</b> , 70, 14.36.1-14.36.14	11
165	Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6. <b>2015</b> , 47, 122-32	23
164	Breast Cancers with Brain Metastases. <b>2015</b> , 113-119	
163	Breast. <b>2015</b> , 183-215	
162	Radiation therapy in the locoregional treatment of triple-negative breast cancer. <b>2015</b> , 16, e113-22	64
161	An overview of triple negative breast cancer for surgical oncologists. <b>2015</b> , 24, 276-83	21
160	Luteinizing hormone as a key player in the cognitive decline of Alzheimer® disease. <b>2015</b> , 76, 48-56	18
159	Risikofaktoren und Prävention des Mammakarzinoms. <b>2015</b> , 21, 202-210	7
158	Genetische Risikofaktoren am Beispiel des familiären Mammakarzinoms. <b>2015</b> , 30, 139-142	1
157	Genotype/Phenotype correlations in patients with hereditary breast cancer. <b>2015</b> , 10, 22-6	12
156	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. <b>2015</b> , 75, 41-50	54
155	Präventive operative Optionen für Frauen mit einer familiären Brust- und Eierstockkrebsbelastung. <b>2015</b> , 27, 231-236	
154	Mammakarzinom Update 2014   Die Patientin und der Tumor im Mittelpunkt. <b>2015</b> , 12, 31-43	
153	Breast Cancer Update 2014 - Focus on the Patient and the Tumour. <b>2015</b> , 75, 170-182	8

152	Mammakarzinom Update 2014   Die Patientin und der Tumor im Mittelpunkt. <b>2015</b> , 36, 213-225	
151	Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. <b>2015</b> , 15, 506	11
150	Biomarker für Patientinnen mit metastasiertem Mammakarzinom und das PRAEGNANT-Studiennetzwerk. <b>2015</b> , 12, 85-94	
149	The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. <b>2015</b> , 154, 441-53	49
148	Hereditary breast cancer syndromes and genetic testing. <b>2015</b> , 111, 66-80	26
147	Immunohistochemical characteristics of basal-like breast cancer. <b>2016</b> , 20, 436-443	20
146	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. <b>2016</b> , 35, 44-56	15
145	Association between basal-like phenotype and germline mutations in Korean breast cancer patients. <b>2016</b> , 23, 298-303	6
144	Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis. <b>2016</b> , 7, 65067-65089	61
143	Management and 5-year survival of BRCA1-associated breast cancer patients. <b>2016</b> , 5, 119-124	1
142	Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing. <b>2016</b> , 90, 315-23	9
141	Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival. <b>2016</b> , 68, 702-12	14
140	Breast Cancer: A Molecular and Redox Snapshot. <b>2016</b> , 25, 337-70	10
139	ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer. <b>2016</b> , 23, R381-92	16
138	Immunohistochemistry as a Practical Tool in Molecular Pathology. <b>2016</b> , 140, 766-9	12
137	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <b>2016</b> , 7, 11375	64
136	Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. <b>2016</b> , 14, 8	25
135	Basics of Oncology. <b>2016</b> ,	5



134	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3764-73	12.9	438
133	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. <b>2016</b> , 155, 597-601		19
132	Cancer of the Breast: An Overview. <b>2016</b> , 147-209		
131	Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer. <b>2016</b> , 49, 253-9		4
130	Single-base LOH can be used as Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes. <b>2017</b> , 23, 479-481		1
129	Low Expression of Estrogen Receptor and Progesterone Receptor in Human Breast Cancer Tissues Is Associated With High-Grade Human Cytomegalovirus Protein Expression. <b>2017</b> , 17, 526-535.e1		10
128	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. <b>2017</b> , 22, 1086-1093		53
127	FOXC1: an emerging marker and therapeutic target for cancer. <b>2017</b> , 36, 3957-3963		64
126	Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast. <b>2017</b> , 14, 1971-1978		9
125	Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations. <b>2017</b> , 209, 920-928		35
124	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. <b>2017</b> , 16, 173-179		2
123	Managing BRCA Mutation Carriers. <b>2017</b> ,		
122	Beratung junger Frauen mit hereditärer Belastung für Brust- und Eierstockkrebs. <b>2017</b> , 32, 37-41		2
121	Pathology and Molecular Pathology of Breast Cancer. <b>2017</b> , 173-231		0
120	The Preventive Intervention of Hereditary Breast Cancer. <b>2017</b> , 1026, 41-57		9
119	Hereditäre Tumordiagnostik [Mammakarzinom: BRCA1, BRCA2 und derzeitiger Stand der Multigenanalysen. <b>2017</b> , 77, 36-40		
118	Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population. <b>2018</b> , 15, 3068-3074		4
117	Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials. <b>2017</b> , 38, 18-23		3

116	GWAS in Breast Cancer. <b>2017</b> ,	1
115	Clinical and genetic characterization of hereditary breast cancer in a Chinese population. <b>2017</b> , 15, 19	13
114	Mammography and ultrasound effective features in differentiating basal-like and normal-like subtypes of triple negative breast cancer. <b>2017</b> , 8, 79670-79679	2
113	Molecular Testing in Breast Cancer. <b>2017</b> , 257-269	
112	Molecular diagnosis in breast cancer. <b>2018</b> , 24, 71-82	3
111	Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer. <b>2018</b> , 123, 74-82	16
110	Pathologic Evaluation of Triple-Negative Breast Cancer. <b>2018</b> , 1-22	2
109	Pathology of Breast Cancer. <b>2018</b> , 177-191	
108	Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images. <b>2018</b> , 27, 317-328	152
107	Triple negative breast cancer: new therapeutic approaches and BRCA status. <b>2018</b> , 126, 371-379	28
106	Personalized prevention in high risk individuals: Managing hormones and beyond. <b>2018</b> , 39, 139-147	15
105	Invasive breast carcinomas with ATM gene variants of uncertain significance share distinct histopathologic features. <b>2018</b> , 24, 291-297	1
104	Molecular subtyping of breast cancer improves identification of both high and low risk patients. <b>2018</b> , 57, 58-66	8
103	Practical consensus recommendations on management of triple-negative metastatic breast cancer. <b>2018</b> , 7, 127-131	3
102	Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. <b>2018</b> , 8, e023115	2
101	BRCA1-Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression. <b>2018</b> , 10,	8
100	Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas. <b>2018</b> , 42, 1262-1272	2
99	Association of SPARC gene polymorphisms rs3210714 and rs7719521 with VEGF expression and utility of Nottingham Prognostic Index scoring in breast cancer in a sample of Egyptian women. <b>2018</b> , 45, 2313-2324	5

98	Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with Mutations. <b>2018</b> , 21, 297-305	4
97	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. <b>2018</b> , 78, 6329-6338	13
96	BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations. <b>2018</b> , 18, e1217-e1227	5
95	Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. <b>2018</b> , 36, 378-388	7
94	Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. <b>2019</b> , 38, e100852	32
93	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. <b>2019</b> , 19, 695	2
92	Molecular Classification and Prognostic Signatures of Breast Tumors. <b>2019</b> , 129-138	
91	Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy. <b>2019</b> , 39, 3863-3869	7
90	GSIAR: gene-subcategory interaction-based improved deep representation learning for breast cancer subcategorical analysis using gene expression, applicable for precision medicine. <b>2019</b> , 57, 2483-2515	3
89	Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. <b>2019</b> , 94, 1084-1098	22
88	Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. <b>2019</b> , 42, 215-231	10
87	BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. <b>2019</b> , 21, 51	7
86	EZH2 Is Overexpressed in -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4351-4362	12.9 23
85	WITHDRAWN: A novel insight of Asp193His mutation on epigenetic methyltransferase activity of human EZH2 protein: An in-silico approach. <b>2019</b> ,	
84	Low Prevalence of the Four Common Colombian Founder Mutations in and in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer. <b>2019</b> , 24, e475-e479	1
83	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. <b>2019</b> , 144, 1195-1204	18
82	A novel insight of Asp193His mutation on epigenetic methyltransferase activity of human EZH2 protein: An in-silico approach. <b>2019</b> , 19, 258-267	1
81	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. <b>2019</b> , 133, 58-73	20

80	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <b>2020</b> , 52, 56-73	56
79	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. <b>2020</b> , 122, 483-490	6
78	Mutations in and differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <b>2021</b> , 1, 1188-1203	43
77	The role of pathologists in recognition of morphologic and biologic features of genetically mutated breast cancer. <b>2020</b> , 26, 1583-1588	1
76	Impact of Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <b>2020</b> , 12,	6
75	Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer. <b>2020</b> , 71, 261-269	
74	Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors. <b>2020</b> , 65, 577-587	9
73	Establishment and Characterization of a Brca1, p53 Mouse Mammary Tumor Cell Line. <b>2020</b> , 21,	3
72	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. <b>2020</b> , 12,	8
71	Local Treatment of Triple-Negative Breast Cancer. <b>2021</b> , 27, 32-40	0
70	The Role of -Mutated Tumor Microenvironment in Breast Cancer. <b>2021</b> , 13,	5
69	Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers. <b>2021</b> , 14, 101012	9
68	Overview of recent advances in metastatic triple negative breast cancer. <b>2021</b> , 12, 164-182	9
67	Identification of Eleven Novel Mutations in Tunisia: Impact on the Clinical Management of Related Cancers. <b>2021</b> , 11, 674965	1
66	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <b>2021</b> , 19, 77-102	131
65	Assessing Genetic Variants of Uncertain Significance: The Example of Breast Cancer.	2
64	Unclassified Variants in the Breast Cancer Susceptibility Genes BRCA1 and BRCA2. <b>2009</b> , 49-73	1
63	Biology and Treatment of Basal-Like Breast Cancer. <b>2013</b> , 91-109	2

62	Pathology of BRCA Tumors. <b>2017</b> , 89-117	1
61	Cancer of the Breast. <b>2008</b> , 1875-1943	8
60	Triple-Negative and Basal-like Carcinoma. <b>2012</b> , 446-478	1
59	Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 Functions. <b>2009</b> , 133, 1822-5	7
58	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes.	2
57	Expression of HIF-1 $\alpha$ and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy. <b>2015</b> , 10, e0129356	21
56	c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression. <b>2015</b> , 6, 11863-81	6
55	The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. <b>2014</b> , 19, 605-18	97
54	Spectrum of Germline and Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome. <b>2020</b> , 12,	7
53	The Culturable Microbial and Chemical Qualities of Some Waters Used for Drinking and Domestic Purposes in a Typical Rural Setting of Southwestern Nigeria. <b>2005</b> , 5, 1041-1048	3
52	Carcinoma of the Breast With Medullary-like Features: Diagnostic Challenges and Relationship With BRCA1 and EZH2 Functions. <b>2009</b> , 133, 1822-1825	18
51	Basal-like breast carcinoma: from expression profiling to routine practice. <b>2009</b> , 133, 860-8	58
50	Clinical significance of basal-like breast cancer in Chinese women in Heilongjiang province. <b>2012</b> , 13, 2735-8	4
49	Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. <b>2014</b> , 15, 10577-83	18
48	Genetic Markers in Breast Tumors with Hereditary Predisposition. <b>2008</b> , 85-105	
47	Genetic Modifiers of Risk of BRCA1- and BRCA2-Related Breast and Ovarian Cancers. <b>2009</b> , 107-129	
46	Gene Expression Profiling in Breast Cancer. <b>2009</b> , 123-136	
45	The Genetics of Breast Cancer. <b>2009</b> , 39-54	

- 44 Common Genetic Susceptibility Loci. **2010**, 301-320
- 43 Surgical Management of Inherited Susceptibility to Breast Cancer. **2010**, 61-78
- 42 Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer. **2009**, 3, 39-47
- 41 Genetics of Hereditary Breast Cancer. **2010**, 41-51
- 40 Response to Paclitaxel in Node-positive Triple Negative Breast Cancer. *[Chapchi] Journal Taehan Oekwa Hakhoe*, **2010**, 79, 173
- 39 Le phhômme mēastatique. Paramēres pronostiques et prđictifs. Intfēēventuel des signatures molēculaires. **2010**, 13-22
- 38 Hereditary Breast Cancer Syndromes. **2011**, 51-104
- 37 Familial Breast Cancer. **2011**, 279-286
- 36 Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer. **2011**, 050-066
- 35 Understanding Triple-Negative Breast Cancer. **2013**, 97-116
- 34 Breast Cancer Invasion and Metastasis. **2013**, 27-56 1
- 33 Breast Cancer Prevention. **2014**, 445-489
- 32 Discovery and Characterization of Cancer Genetic Susceptibility Alleles. **2014**, 309-321.e3
- 31 The genetics of breast cancer, risk-reducing surgery and prevention. **2014**, 127-145
- 30 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. *Cancer Drug Discovery and Development*, **2015**, 381-412 0.3
- 29 Biomarkers for Early Detection of Familial Breast Cancer. **2015**, 167-190
- 28 Hereditary Ovarian Cancer. *Comprehensive Gynecology and Obstetrics*, **2017**, 15-35 0
- 27 A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran. *Iranian Journal of Cancer Prevention*, **2017**, In Press,

26	Basic Molecular Pathology in Breast Carcinoma. <b>2018</b> , 357-372		0
25	Molecular-biological characteristics of triple negative breast cancer. <b>2018</b> , 17, 23-27	0.4	
24	[Hereditary breast carcinomas pathologist's perspective]. <i>Annales De Pathologie</i> , <b>2020</b> , 40, 78-84	0.3	0
23	Classification moléculaire des cancers du sein. Implications pratiques. <b>2007</b> , 289-295		
22	Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.		1
21	Understanding and treating triple-negative breast cancer. <i>Oncology</i> , <b>2008</b> , 22, 1233-9; discussion 1239-40, 1243	1.8	167
20	Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer. <i>International Journal of Molecular and Cellular Medicine</i> , <b>2016</b> , 5, 114-22	1.2	3
19	Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2021</b> , 14, 322-337	1.4	1
18	Genanalysen in der Gynäkologie: Basis für die personalisierte Prävention und Therapie.		
17	Triple-negative breast cancer - an aggressive subtype of breast cancer. <b>2022</b> , 1-28		
16	Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer. <b>2022</b> , 87-112		
15	Statistical methods for Mendelian models with multiple genes and cancers.. <i>Genetic Epidemiology</i> , <b>2022</b> ,	2.6	1
14	Breast. <b>2022</b> , 253-292		
13	The Ascendant Role of Machine Learning Algorithms in the Prediction of Breast Cancer and Treatment Using Telehealth. <b>2022</b> , 285-316		
12	BRCA1 and BRCA2 germline mutation analysis from a cohort of 1,267 high-risk breast cancer patients in Brazil.		0
11	Update Breast Cancer 2022 Part 3 [Early-Stage Breast Cancer. <b>2022</b> , 82, 912-921		0
10	Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials. <b>2022</b> , 13, 14827-14839		0
9	Hereditary breast cancer: syndromes, tumour pathology and molecular testing. <b>2023</b> , 82, 70-82		4

- 8 Reliability of CD44, CD24, and ALDH1A1 immunohistochemical staining: Pathologist assessment compared to quantitative image analysis. 9,
- 7 Update Mammakarzinom 2022 Teil 3 [Brustkrebs in frühen Krankheitsstadien. **2022**, 19, 365-375
- 6 Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs. **2023**, 7,
- 5 Low Expression of BRCA1 as a Potential Relapse Predictor in B-Cell Acute Lymphoblastic Leukemia. **2023**, 45, e167-e173
- 4 BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
- 3 Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. **2023**, 153, 40055
- 2 Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study. **2023**, 15,
- 1 Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA. **2023**, 24, 7235